Anthony Ofori | Medical Graduate in General Medicine | Founder, WellNest Central
Last updated: October 20, 2026
This article is for general health education and does not replace individual medical advice, diagnosis, or treatment.
Being offered a medicine usually associated with diabetes can be confusing when you do not have diabetes. You might wonder whether your diagnosis has changed or whether the prescription was a mistake. With some SGLT2 inhibitors, the reason can be kidney protection rather than treatment of high blood sugar.
These medicines can benefit selected adults with chronic kidney disease, including some people without diabetes. They are not suitable for everyone, and the decision depends on the particular medicine, kidney results, other conditions, and safety considerations.
What are SGLT2 inhibitors?
SGLT2 inhibitors are prescription medicines that act on a transport system in the kidneys. They change how the kidneys handle glucose and sodium. Examples include dapagliflozin and empagliflozin; the approved uses and precautions should be checked for the specific product.
The National Kidney Foundation’s overview of SGLT2 inhibitors explains their role in kidney and heart care. Their benefits are not limited to lowering a glucose reading. This helps explain why a clinician might discuss one even if your A1C is normal.
Do not infer a new diabetes diagnosis from the drug name alone. Ask the prescriber to write down its purpose in your treatment plan. That makes future medication reviews easier and helps other healthcare professionals understand why you are taking it.
Who might benefit without diabetes?
The strongest answer is individual: some adults with chronic kidney disease may benefit, but “kidney disease” covers many different situations. Your estimated glomerular filtration rate, urine albumin, the cause of kidney disease, and any heart failure all help guide the discussion.
The American Kidney Fund’s explanation of SGLT2 medicines notes that some have approved uses in people with chronic kidney disease or heart failure without type 2 diabetes. That does not mean every person with a single abnormal kidney test should start treatment.
A clinician may first need to confirm that an abnormality is persistent and understand its cause. People with certain kidney conditions, those receiving dialysis, and people with other important medical circumstances may require different approaches. Type 1 diabetes also raises distinct safety concerns and should not be treated as interchangeable with type 2 diabetes.
Bring both blood and urine results to the appointment. Our article on urine albumin testing explains why sample preparation and interpretation matter. A kidney-protection discussion often requires more information than creatinine alone.
What should be checked before starting?
A medication review should include blood pressure, kidney function, current fluid status, and the full prescription and supplement list. Tell your clinician about frequent genital infections, low blood pressure, recent vomiting, poor food intake, or planned procedures.
The MedlinePlus patient information for dapagliflozin also highlights pregnancy, breastfeeding, alcohol use, ketogenic diets, and surgery as issues to discuss. These are reasons for a careful plan, not a checklist for deciding on your own whether to take the medicine.
Ask practical questions before the first dose: When is the next review? Who should I call if I become dizzy? Do any other medicines need adjustment? What should I do during an illness that stops me eating or drinking normally?
Cost and access belong in this conversation too. Ask the pharmacy about your actual coverage and refill arrangements. A plan that you cannot obtain consistently needs to be addressed with the prescribing team.
Want help organizing questions about a kidney-protection prescription? Explore WellNest Central’s health education and consultation services.
Will your kidney blood test change?
An early change in estimated filtration can occur after starting an SGLT2 inhibitor. It needs to be interpreted alongside the size of the change, blood pressure, hydration, symptoms, and other medicines. A small expected change and an acute kidney problem are not the same thing.
The UK Kidney Association’s clinical guideline discusses interpreting an early eGFR decline in context. Your own clinician should decide whether a result fits the expected response or requires further assessment.
Ask how results will be communicated. If the patient portal flags a value before the clinician has reviewed it, contact the team for interpretation instead of stopping treatment or doubling your water intake automatically.
Which side effects need attention?
Possible problems include genital yeast infections and symptoms related to fluid loss, such as dizziness. Report new itching, irritation, painful urination, or persistent lightheadedness. Your clinician can assess the cause and decide whether treatment or a medication change is needed.
A rarer but important risk is ketoacidosis, which can occur without a very high glucose reading. Nausea, vomiting, abdominal pain, unusual exhaustion, or difficulty breathing while taking an SGLT2 inhibitor need urgent medical advice. The medication guidance advises stopping the medicine and seeking immediate assessment if ketoacidosis is suspected. A normal-looking glucose result does not make those symptoms safe to ignore.
Seek emergency help for severe breathing difficulty, collapse, or confusion. Do not spend time trying to manage a severe illness through an educational consultation.
Make a plan for illness and procedures
SGLT2 medicines may need to be withheld temporarily around certain operations, prolonged fasting, or acute illness. The timing varies by product and circumstances. Get written instructions from the prescribing or procedural team, including when it is safe to restart.
This is especially useful before a colonoscopy or planned surgery, when preparation can change food and fluid intake. Tell every relevant team which medicine you take. Do not wait until the procedure morning to ask.
The goal of treatment is a worthwhile long-term benefit with a clear safety plan. You should know why the medicine was chosen, how it will be monitored, and what situations require prompt contact.
For help preparing an informed conversation with your healthcare professional, book a health education consultation.
